{name}
{subtitle}
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
city
~37 mi. (Newcastle upon Tyne, United Kingdom, +11 more cities)
facility
Freeman Hospital
drug
BAY2416964, +1 more drug
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
city
~37 mi. (Newcastle upon Tyne, United Kingdom, +15 more cities)
facility
Freeman Hospital
biomarker
ARID1A Loss, +125 more biomarkers
drug
elimusertib, +1 more drug
drug type
immunotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~78 mi. (Middlesbrough, United Kingdom, +163 more cities)
facility
The James Cook University Hospital ( Site 0730)
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
city
~78 mi. (Middlesbrough, United Kingdom, +126 more cities)
facility
Local Institution
drug
nivolumab, +2 more drugs
drug type
chemotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~96 mi. (Edinburgh, United Kingdom, +226 more cities)
facility
Western General Hospital ( Site 0531)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
city
~96 mi. (Edinburgh, United Kingdom, +27 more cities)
facility
Western General Hospital ( Site 1402)
drug
belzutifan, +4 more drugs
drug type
immunotherapy, +1 more type
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)
city
~96 mi. (Edinburgh, United Kingdom, +28 more cities)
facility
Western General Hospital ( Site 3402)
drug
belzutifan, +5 more drugs
drug type
immunotherapy, +1 more type